TBPH Q2 2025 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+83.7% YoY

Gross Profit

$16M60.0% margin

Operating Income

-$3M-10.4% margin

Net Income

$55M209.3% margin

EPS (Diluted)

$1.08

QoQ Revenue Growth

+70.2%

Cash Flow

Operating Cash Flow

$208M

Free Cash Flow

$208M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$426M

Total Liabilities

$201M

Stockholders' Equity

$225M

Cash & Equivalents

$282M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$14M	+83.7%
Gross Profit	$16M	$4M	+265.1%
Operating Income	-$3M	-$16M	+82.6%
Net Income	$55M	-$17M	+431.8%

Revenue Segments

YUPELRI Monotherapy

$23M47%

Collaborative Arrangement Revenue

$19M38%

License

$8M15%